Ensoma is pleased to sponsor a clinical trial for a new in vivo approach to gene therapy. The trial is open for recruitment amongst adult males living with X-linked CGD. Multiple sites are open in the United States. Additional sites are being opened soon in the United States and United Kingdom.
The Phase 1/2 trial will evaluate EN-374, Ensoma’s in vivo gene therapy for X-CGD.
You can learn more and read the eligibility criteria on clinicaltrials.gov (study identifier NCT06876363). Additional information is available at www.ennovatetrial.com and www.ensoma.com.
